{"id":59252,"date":"2026-03-11T13:55:25","date_gmt":"2026-03-11T05:55:25","guid":{"rendered":"https:\/\/flcube.com\/?p=59252"},"modified":"2026-03-11T13:55:26","modified_gmt":"2026-03-11T05:55:26","slug":"jj-files-tecvayli-line-extension-with-ema-bcma-bispecific-seeks-earlier-use-in-second-line-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59252","title":{"rendered":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced the <strong>submission of a Type II variation application<\/strong> to the <strong>European Medicines Agency (EMA)<\/strong> seeking <strong>indication extension<\/strong> for <strong>TECVAYLI (teclistamab)<\/strong> as <strong>monotherapy<\/strong> for <strong>relapsed\/refractory multiple myeloma (RRMM)<\/strong> patients who have received <strong>at least one prior therapy<\/strong>. The filing, supported by <strong>Phase III MajesTEC-9 trial data<\/strong> showing <strong>71% reduction in disease progression risk<\/strong> and <strong>40% reduction in death risk<\/strong> versus standard of care, positions the <strong>BCMA\/CD3 bispecific<\/strong> for <strong>second-line use<\/strong> in a <strong>heavily pre-treated, refractory population<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-submission-overview\">Regulatory Submission Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Medicines Agency (EMA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Type II variation (indication extension)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TECVAYLI (teclistamab)<\/td><\/tr><tr><td><strong>Requested Indication<\/strong><\/td><td>Monotherapy for RRMM after \u22651 prior therapy (second-line expansion)<\/td><\/tr><tr><td><strong>Current EU Approval<\/strong><\/td><td>RRMM after \u22653 prior therapies (August 2022) \u2013 fourth-line setting<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Phase III MajesTEC-9 trial (n=614)<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Pomalidomide + bortezomib + dexamethasone (PVd) or carfilzomib + dexamethasone (Kd)<\/td><\/tr><tr><td><strong>Submission Date<\/strong><\/td><td>10\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-majestec-9-clinical-evidence\">MajesTEC-9 Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Teclistamab<\/th><th>Standard of Care (PVd\/Kd)<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td>Superior<\/td><td>\u2014<\/td><td><strong>71% reduction in disease progression or death risk<\/strong><\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>Superior<\/td><td>\u2014<\/td><td><strong>40% reduction in death risk<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Predominantly refractory to anti-CD38 mAbs and lenalidomide<\/td><td>\u2014<\/td><td>High-unmet-need, heavily pre-treated<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Clinically manageable; consistent with known profile<\/td><td>\u2014<\/td><td>No new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Study Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> 614 RRMM patients; early as second-line<\/li>\n\n\n\n<li><strong>Refractoriness:<\/strong> Anti-CD38 monoclonal antibodies and lenalidomide<\/li>\n\n\n\n<li><strong>Setting:<\/strong> Post-initial therapy failure (not triple-class refractory)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Teclistamab Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Off-the-shelf (ready-to-use) bispecific T-cell engager<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>BCMA (B-cell maturation antigen on myeloma cells) + CD3 (T-cell receptor)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Redirects patient T-cells to target and eliminate BCMA-expressing myeloma cells<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Subcutaneous injection (no CAR-T manufacturing required)<\/td><\/tr><tr><td><strong>Current EU Label<\/strong><\/td><td>Fourth-line+ (\u22653 prior therapies including IMiD, PI, anti-CD38)<\/td><\/tr><tr><td><strong>U.S. Status<\/strong><\/td><td>Approved (similar fourth-line indication); second-line combo approval March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-impact\">Strategic Context &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Line of Therapy Expansion<\/strong><\/td><td>Moves from fourth-line to second-line \u2013 <strong>3x addressable patient population increase<\/strong> in EU<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Challenges CAR-T therapies (cilta-cel, ide-cel) in earlier relapse; convenience advantage (off-the-shelf vs. manufacturing)<\/td><\/tr><tr><td><strong>MajesTEC Program<\/strong><\/td><td>MajesTEC-9 supports monotherapy; MajesTEC-3 (combo with daratumumab) approved U.S. March 2026<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Analysts project <strong>\u20ac3-5 billion peak EU sales<\/strong> with second-line expansion; accelerates trajectory vs. CAR-T competition<\/td><\/tr><tr><td><strong>Safety Consistency<\/strong><\/td><td>Manageable profile supports earlier-line use where patients have better performance status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>EU Line Setting<\/th><th>TECVAYLI Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>BMS\/Janssen<\/strong><\/td><td>Abecma (ide-cel)<\/td><td>Anti-BCMA CAR-T<\/td><td>Second-line approved<\/td><td>Off-the-shelf convenience; no lymphodepletion<\/td><\/tr><tr><td><strong>J&amp;J\/Legend<\/strong><\/td><td>Carvykti (cilta-cel)<\/td><td>Anti-BCMA CAR-T<\/td><td>Second-line approved<\/td><td>Subcutaneous vs. IV infusion; broader site availability<\/td><\/tr><tr><td><strong>Sanofi<\/strong><\/td><td>Sarclisa (isatuximab)<\/td><td>Anti-CD38 mAb<\/td><td>Second-line (combo)<\/td><td>Bispecific T-cell engagement vs. mAb-mediated killing<\/td><\/tr><tr><td><strong>J&amp;J<\/strong><\/td><td><strong>TECVAYLI<\/strong><\/td><td><strong>BCMA\/CD3 bispecific<\/strong><\/td><td><strong>Fourth-line (current); second-line (pending)<\/strong><\/td><td><strong>First bispecific with second-line monotherapy data<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-launch-outlook\">Regulatory Timeline &amp; Launch Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Timeline<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>EMA Review<\/strong><\/td><td>2026-2027<\/td><td>Type II variation assessment; CHMP opinion anticipated Q4 2026<\/td><\/tr><tr><td><strong>EU Approval<\/strong><\/td><td>Q1-Q2 2027<\/td><td>Conditional or full marketing authorization<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Q2-Q3 2027<\/td><td>Hospital formulary access; myeloma center education<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td>2027-2028<\/td><td>HTA negotiations (NICE, IQWiG, etc.)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EMA review timelines, indication expansion, and competitive positioning for TECVAYLI in second-line multiple myeloma. Actual results may differ due to regulatory decisions, HTA negotiations, and competitive dynamics with CAR-T therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced the submission of a Type II variation application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59253,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[150,149,38,28,858],"class_list":["post-59252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-jj","tag-johnson-johnson","tag-market-approval-filings","tag-multi-specific-antibodies","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59252\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59252\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:55:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T05:55:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma\",\"datePublished\":\"2026-03-11T05:55:25+00:00\",\"dateModified\":\"2026-03-11T05:55:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252\"},\"wordCount\":540,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1103.webp\",\"keywords\":[\"J&amp;J\",\"Johnson &amp; Johnson\",\"Market approval filings\",\"Multi-specific antibodies\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59252#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59252\",\"name\":\"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1103.webp\",\"datePublished\":\"2026-03-11T05:55:25+00:00\",\"dateModified\":\"2026-03-11T05:55:26+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\\\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\\\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59252\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1103.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59252#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59252","og_locale":"en_US","og_type":"article","og_title":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.","og_url":"https:\/\/flcube.com\/?p=59252","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:55:25+00:00","article_modified_time":"2026-03-11T05:55:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59252#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59252"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma","datePublished":"2026-03-11T05:55:25+00:00","dateModified":"2026-03-11T05:55:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59252"},"wordCount":540,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59252#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","keywords":["J&amp;J","Johnson &amp; Johnson","Market approval filings","Multi-specific antibodies","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59252#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59252","url":"https:\/\/flcube.com\/?p=59252","name":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59252#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59252#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","datePublished":"2026-03-11T05:55:25+00:00","dateModified":"2026-03-11T05:55:26+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking indication extension for TECVAYLI (teclistamab) as monotherapy for relapsed\/refractory multiple myeloma (RRMM) patients who have received at least one prior therapy. The filing, supported by Phase III MajesTEC-9 trial data showing 71% reduction in disease progression risk and 40% reduction in death risk versus standard of care, positions the BCMA\/CD3 bispecific for second-line use in a heavily pre-treated, refractory population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59252#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59252"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59252#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","width":1080,"height":608,"caption":"J&J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59252#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J Files TECVAYLI Line Extension with EMA \u2013 BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59252"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59252\/revisions"}],"predecessor-version":[{"id":59254,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59252\/revisions\/59254"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59253"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}